Approval · Notice of Compliance 21231 · 2018
SOLIRIS: Notice of Compliance 21231
Issued August 20, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21231
- Date
- August 20, 2018
- Company
- Alexion Pharma GmbhBaar, --, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: generalized myasthenia gravis (gmg)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SOLIRIS | Not yet assigned | — |
Medicinal ingredients
- ECULIZUMAB 10 MG per ML